Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
BILLERICA, Mass.--(BUSINESS WIRE)--May 22, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference. Quanterix's presentation is scheduled for Wednesday, May 29, 2024, at 11:40 a.m. ET. The fireside chat will be made available to attendees and to the public via webcast.
马萨诸塞州比勒里卡--(美国商业资讯)--2024年5月22日-- Quanterix 公司 纳斯达克股票代码：QTRX）是一家通过超灵敏生物标志物检测推动科学发现的公司，今天宣布，首席执行官马苏德·托洛伊将在2024年Leerink Partners医疗保健十字路口会议的炉边谈话中发表讲话。Quanterix的演讲定于美国东部时间2024年5月29日星期三上午11点40分举行。炉边谈话将通过网络直播提供给与会者和公众。
Webcast Information
The live webcast of Quanterix's presentation can be accessed here, and from the Investor section of the company' website at www.Quanterix.com. Replays of the presentation will be available for a limited time following the conference.
网络直播信息
可以观看 Quanterix 演讲的网络直播 这里，并来自公司网站的 “投资者” 部分，网址为 www.quanterix.com。演示文稿的重播将在会议结束后的有限时间内提供。
To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix's Simoa technology, visit: www.quanterix.com/simoa-technology/.
要了解有关 Quanterix 的更多信息，请访问 www.quanterix.com/关于。要了解有关 Quanterix 的 Simoa 技术的更多信息，请访问： www.quanterix.com/simoa-techn。
About Quanterix
From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
关于 Quanterix
从发现到诊断，Quanterix的超灵敏生物标志物检测只有通过其无与伦比的灵敏度和灵活性才有可能实现突破。该公司的Simoa技术为早期血液、血清或血浆中的生物标志物检测提供了黄金标准，能够量化远低于定量水平（LoQ）的蛋白质。其行业领先的精密仪器、数字免疫分析技术和经CLIA认证的Accelerator实验室为促进神经病学、肿瘤学、免疫学、心脏病学和传染病领域的疾病理解和管理的研究提供了支持。近二十年来，Quanterix 一直是科学界值得信赖的合作伙伴，推动了在 2,900 多份同行评审期刊上发表的研究。要了解有关这家总部位于马萨诸塞州比尔里卡的公司的更多信息，请访问 https://www.quanterix.com 或者关注我们 推特 和 领英。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522008584/en/
Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
媒体联系人：
PAN 通讯
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
Investor Relations Contact:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com
投资者关系联系人：
Quanterix
弗朗西斯·普鲁尔
(508) -789-1725
ir@quanterix.com
Source: Quanterix Corporation
来源：Quanterix 公司